Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

George Warren, PhD, Lead Author and Principal Scientist at Artelo, said, "We are excited to share the results on this novel ...

Artelo Biosciences advances ART26.12 for psoriasis and CIPN, while ART27.13 shows early promise in cancer-related anorexia ...

Patanjali Ayurved claims a major breakthrough in curing Psoriasis with its herbal medicines Psorogrit and Divya-Taila, as ...

Medically reviewed by Corinne Savides Happel, MD Allergies don't cause psoriasis, but you may be more likely to have ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

Vyne Therapeutics’ attempt to develop a safer, more tolerable BET inhibitor has hit turbulence. | Vyne Therapeutics’ attempt ...

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Passive income is essential in retirement, but building a dependable stream isn't easy. Fortunately, top-tier dividend stocks ...

Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

China’s National Medical Products Administration has given the thumbs up to Akeso Pharmaceuticals Inc.’s ebdarokimab for treating moderate to severe plaque psoriasis in adults. An interleukin ...